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A bs tr ac t
Background
The efficacy of vedolizumab, an α4β7 integrin antibody, in Crohn’s disease is unknown.
Methods
In an integrated study with separate induction and maintenance trials, we assessed 
intravenous vedolizumab therapy (300 mg) in adults with active Crohn’s disease. In 
the induction trial, 368 patients were randomly assigned to receive vedolizumab or 
placebo at weeks 0 and 2 (cohort 1), and 747 patients received open-label vedoliz-
umab at weeks 0 and 2 (cohort 2); disease status was assessed at week 6. In the 
maintenance trial, 461 patients who had had a response to vedolizumab were ran-
domly assigned to receive placebo or vedolizumab every 8 or 4 weeks until week 52.
Results
At week 6, a total of 14.5% of the patients in cohort 1 who received vedolizumab 
and 6.8% who received placebo were in clinical remission (i.e., had a score on the 
Crohn’s Disease Activity Index [CDAI] of ≤150, with scores ranging from 0 to ap-
proximately 600 and higher scores indicating greater disease activity) (P = 0.02); 
a total of 31.4% and 25.7% of the patients, respectively, had a CDAI-100 response 
(≥100-point decrease in the CDAI score) (P = 0.23). Among patients in cohorts 1 and 
2 who had a response to induction therapy, 39.0% and 36.4% of those assigned to 
vedolizumab every 8 weeks and every 4 weeks, respectively, were in clinical remis-
sion at week 52, as compared with 21.6% assigned to placebo (P<0.001 and P = 0.004 
for the two vedolizumab groups, respectively, vs. placebo). Antibodies against ve-
dolizumab developed in 4.0% of the patients. Nasopharyngitis occurred more fre-
quently, and headache and abdominal pain less frequently, in patients receiving 
vedolizumab than in patients receiving placebo. Vedolizumab, as compared with 
placebo, was associated with a higher rate of serious adverse events (24.4% vs. 
15.3%), infections (44.1% vs. 40.2%), and serious infections (5.5% vs. 3.0%).
Conclusions
Vedolizumab-treated patients with active Crohn’s disease were more likely than 
patients receiving placebo to have a remission, but not a CDAI-100 response, at 
week 6; patients with a response to induction therapy who continued to receive 
vedolizumab (rather than switching to placebo) were more likely to be in remission 
at week 52. Adverse events were more common with vedolizumab. (Funded by Mil-
lennium Pharmaceuticals; GEMINI 2 ClinicalTrials.gov number, NCT00783692.)
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Crohn’s disease is a chronic inflam-matory bowel disease.1 Current treatments include glucocorticoids, immunosuppres-
sive agents (i.e., azathioprine, mercaptopurine, 
or methotrexate), and tumor necrosis factor (TNF) 
antagonists.1-3 Many patients do not have a re-
sponse to therapy,4 and treatments are associated 
with important toxic effects.5,6
Natalizumab, a monoclonal antibody that 
modulates gut and brain lymphocyte migration 
by antagonizing α4β1 and α4β7 integrin–mediated 
interactions,7 is efficacious in the treatment of 
multiple sclerosis8,9 and Crohn’s disease.10-12 Its 
use in patients with Crohn’s disease has been 
limited by the development in some patients of 
progressive multifocal leukoencephalopathy (PML), 
an opportunistic brain infection that is caused 
by reactivation of latent JC polyomavirus.13,14
Vedolizumab (Millennium Pharmaceuticals), 
a humanized immunoglobulin G1 monoclonal 
antibody to α4β7 integrin, modulates gut, but 
not brain, lymphocyte trafficking and therefore 
should theoretically be less likely to confer a pre-
disposition to PML.15 Results from phase 2 trials 
suggested a benefit in patients with inflamma-
tory bowel disease.16-18 We conducted integrated 
induction and maintenance trials of vedolizumab 
in patients with moderately to severely active 
Crohn’s disease.
Me thods
Study Oversight
This phase 3, randomized, parallel-group, double-
blind, placebo-controlled study consisted of sepa-
rate induction and maintenance trials. We conduct-
ed the study at 285 medical centers in 39 countries 
from December 2008 to May 2012. (Enrollment 
was discontinued at 15 of these centers; see the 
Supplementary Appendix, available with the full 
text of this article at NEJM.org.) The protocol was 
approved by the institutional review board at 
each participating center. All patients gave writ-
ten informed consent.
The members of the GEMINI 2 steering com-
mittee (see the Supplementary Appendix), which 
was composed of academic investigators, designed 
the trial in conjunction with the sponsor (Millen-
nium Pharmaceuticals). The study was monitored 
by means of onsite visits, with audits conducted 
at centers with high enrollment (see the Supple-
mentary Appendix). The sponsor collected and 
analyzed the data, and the steering committee 
and the sponsor jointly interpreted the data. All 
the authors had full access to the data. The inves-
tigators, the participating institutions, and the 
sponsor agreed to maintain the confidentiality of 
the data. The first two authors wrote the first draft 
of the manuscript, and all the authors contributed 
to subsequent drafts. All the authors made the 
decision to submit the manuscript for publication 
and vouch for the veracity and completeness of the 
data and analyses and for the fidelity of the study 
to the protocol, available at NEJM.org. Editorial 
support was provided by Takeda Pharmaceuti-
cals International and by Complete Healthcare 
Communications and MedLogix Communications, 
funded by Takeda Pharmaceuticals International.
Patients
Eligible patients were 18 to 80 years of age, had 
had Crohn’s disease for at least 3 months, had a 
score of 220 to 450 on the Crohn’s Disease Activ-
ity Index (CDAI, on which scores range from 0 to 
approximately 600, with higher scores indicating 
greater disease activity19), and had one of the fol-
lowing: a serum C-reactive protein level higher than 
2.87 mg per liter, colonoscopic findings showing 
3 or more large ulcers or 10 or more aphthous ul-
cers, or fecal calprotectin concentrations of more 
than 250 μg per gram of stool plus evidence of ul-
cers on computed tomography or magnetic reso-
nance enterography, small-bowel radiography, or 
capsule endoscopy. Eligible patients had had no re-
sponse to or had had unacceptable side effects from 
one or more of the following: glucocorticoids, im-
munosuppressive agents (i.e., azathioprine, mercap-
topurine, or methotrexate), or TNF antagonists (Ta-
ble S1 in the Supplementary Appendix). Stable doses 
of oral prednisone (≤30 mg per day) or budesonide 
(≤9 mg per day), immunosuppressive agents, me-
salamine, and antibiotics were permitted. Patients 
were not eligible if they had received previous treat-
ment with vedo liz umab, natalizumab, efalizumab, 
or rituximab. Treatment with adalimumab within 
30 days before enrollment and treatment with in-
flix imab or certolizumab pegol within 60 days be-
fore enrollment was not permitted. Patients with 
a stoma, more than three small-bowel resections, 
the short-bowel syndrome, extensive colonic resec-
tion, intestinal stricture, abdominal abscess, active 
or latent tuberculosis, or cancer were excluded.
Screening assessments included physical and 
neurologic examinations; questionnaires designed 
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to identify possible symptoms of PML (see the 
Supplementary Appendix); blood and stool tests, 
including measurement of fecal calprotectin and 
C-reactive protein levels; and the Inflammatory 
Bowel Disease Questionnaire (IBDQ, on which 
scores range from 32 to 224, with higher scores 
indicating better quality of life).
Randomization
In the double-blind induction trial (cohort 1), pa-
tients were randomly assigned, in a 3:2 ratio, to re-
ceive intravenous vedolizumab, at a dose of 300 mg, 
or placebo at weeks 0 and 2 and were followed 
through week 6, at which time disease status was 
assessed. Randomization was stratified accord-
ing to status with respect to concomitant use of 
glucocorticoids and according to status with re-
spect to concomitant use of immunosuppressive 
agents, prior use of TNF antagonists, or both. 
The proportion of patients with previous expo-
sure to TNF antagonists was limited to 50%.
To fulfill the sample-size requirements for the 
maintenance trial, additional patients were en-
rolled in an open-label group (cohort 2), which re-
ceived the same vedolizumab induction regimen 
that was used for the patients assigned to ved o liz-
umab in cohort 1. Patients from both cohorts who 
had a clinical response (i.e., ≥70-point decrease in 
the CDAI score) with vedolizumab at week 6 were 
randomly assigned, in a 1:1:1 ratio, to continue 
in a blinded fashion to receive vedolizumab every 
8 weeks, vedolizumab every 4 weeks, or placebo, 
for up to 52 weeks. Randomization was stratified 
according to participation in cohort 1 or 2 during 
induction; concomitant use of glucocorticoids; 
and concomitant use of immunosuppressive 
agents, prior use of TNF antagonists, or both. 
Patients who did not have a clinical response at 
week 6 to vedolizumab induction therapy re-
ceived vedolizumab at a dose of 300 mg every 
4 weeks and were followed through week 52. 
Patients in the placebo group of cohort 1 con-
tinued to receive placebo and were also followed 
through week 52.
Randomization was computer-generated and 
was performed at a central location. Glucocor-
ticoids were tapered in patients who had a re-
sponse at week 6, according to a prespecified 
regimen; immunosuppressive agents were dis-
continued in patients at U.S. sites (see the Sup-
plementary Appendix). The use of other con-
comitant medications remained constant.
Follow-up
Study visits were scheduled at weeks 0, 2, 4, and 6 
in the trial of induction therapy and every 4 weeks 
thereafter during the trial of maintenance therapy 
until week 52. Adverse events, CDAI score, neu-
rologic symptoms of PML as assessed by means 
of questionnaires (see the Supplementary Appen-
dix), the use of concomitant medications, and the 
presence or absence of fistulae were evaluated at 
all visits. Blood testing, including measurement 
of C-reactive protein levels, serum vedolizumab 
concentrations, and antibodies against vedoliz-
umab, was performed at baseline and through-
out the study. Testing for JC virus antibodies was 
not performed because a validated assay was not 
available.
End-Point Measures
The two primary end points in the trial of induc-
tion therapy were clinical remission (CDAI score of 
≤150 points19) and CDAI-100 response (≥100-point 
decrease in the CDAI score) at week 6; the second-
ary end point was the mean change in C-reactive 
protein levels from baseline to week 6. In the 
trial of maintenance therapy, the primary end 
point was clinical remission at week 52, and the 
secondary end points (in ranked order) were 
CDAI-100 response, glucocorticoid-free remis-
sion (defined as clinical remission at week 52 
without glucocorticoid therapy), and durable 
clinical remission (defined as clinical remission 
at ≥80% of study visits, including the final visit) 
at week 52. Adverse events were classified ac-
cording to the Medical Dictionary for Regulatory 
Activities,20 version 15, and were analyzed in the 
safety population, which included all patients 
who received any amount of study drug during 
the course of the study.
Statistical Analysis
Descriptive statistics were used to summarize 
demographic characteristics. The proportions of 
patients with clinical remission and a CDAI-100 
response at week 6 were analyzed with the use of 
a Cochran–Mantel–Haenszel chi-square test with 
adjustment for stratification factors. Patients who 
withdrew from the study prematurely were clas-
sified as having had treatment failure (Table S2 
in the Supplementary Appendix).
A combination of the Hochberg method and 
sequential testing was used to maintain the 
overall type I error rate at a 5% significance 
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level. If the P value for one of the two primary 
end points was greater than 0.05, the other 
P value was considered to indicate statistical 
significance only if it was 0.025 or lower. Nine 
subgroup analyses were prespecified; risk dif-
ferences and 95% confidence intervals were 
determined for the proportions of patients in 
the vedolizumab and placebo groups who were 
in remission and who had CDAI-100 responses 
at week 6.
The proportions of patients who met the cri-
teria for the end points during the trial of main-
tenance therapy were analyzed in a similar way. 
End points in that trial were tested for signifi-
cance in a prespecified ranked order, with the 
Hochberg method applied to maintain the alpha 
level at 5% in the comparison of the two vedoliz-
umab regimens with placebo. Exploratory analy-
ses of end points were not adjusted for multiple 
comparisons. Continuous outcomes with respect 
to CDAI score, IBDQ score, and glucocorticoid 
use over time were examined by means of an 
analysis of covariance; data on C-reactive protein 
levels were analyzed with the use of the Wil-
coxon rank-sum test.
For the trial of induction therapy, we calcu-
lated that with 370 patients, the study would 
have 91% power to detect a 16% difference in 
clinical remission rates and 82% power to detect 
a 15% difference in CDAI-100 response rates 
between the vedolizumab and placebo groups, 
assuming clinical remission rates of 37% and 
21% with vedolizumab and placebo, respectively, 
and CDAI-100 response rates of 46% and 31%, 
Table 1. Demographic and Baseline Clinical Characteristics and History of Crohn’s Disease Medication among Patients in the Induction Trial.*
Characteristic
Placebo
(N = 148) Vedolizumab
Total
(N = 1115)
Cohort 1
(N = 220)
Cohort 2
(N = 747)
Combined
(N = 967)
Age — yr 38.6±13.2 36.3±11.6 35.6±12.0 35.7±11.9 36.1±12.1
Male sex — no. (%) 69 (46.6) 105 (47.7) 346 (46.3) 451 (46.6) 520 (46.6)
White race — no. (%)† 124 (83.8) 182 (82.7) 689 (92.2) 871 (90.1) 995 (89.2)
Body weight — kg 68.7±18.9 67.1±19.1 70.8±19.6 69.9±19.5 69.8±19.4
Current smoker — no. (%) 34 (23.0) 54 (24.5) 210 (28.1) 264 (27.3) 298 (26.7)
Duration of disease — yr 8.2±7.8 9.2±8.2 9.2±7.6 9.2±7.8 9.0±7.8
CDAI score‡ 325±78 327±71 322±67 323±68 324±69
Median C-reactive protein — mg/liter§ 13.7 15.3 10.2 10.6 11.5
Median fecal calprotectin — µg/g¶ 653 852 657 688 686
Disease site — no. (%)
Ileum only 21 (14.2) 37 (16.8) 123 (16.5) 160 (16.5) 181 (16.2)
Colon only 43 (29.1) 62 (28.2) 211 (28.2) 273 (28.2) 316 (28.3)
Ileum and colon 84 (56.8) 121 (55.0) 413 (55.3) 534 (55.2) 618 (55.4)
Concomitant medications for Crohn’s disease 
— no. (%)‖
Glucocorticoids only 45 (30.4) 67 (30.5) 269 (36.0) 336 (34.7) 381 (34.2)
Immunosuppressive agents only 25 (16.9) 37 (16.8) 119 (15.9) 156 (16.1) 181 (16.2)
Glucocorticoids and immunosuppressive 
agents
26 (17.6) 38 (17.3) 125 (16.7) 163 (16.9) 189 (17.0)
No glucocorticoids or immunosuppres-
sive agents
52 (35.1) 78 (35.5) 234 (31.3) 312 (32.3) 364 (32.6)
Prednisone-equivalent dose — mg
Median 20.0 20.0 20.0 20.0 20.0
Interquartile range 10.0–30.0 10.0–20.0 12.5–30.0 10.0–30.0 10.0–30.0
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respectively.11,16,21-26 For the trial of maintenance 
therapy, we calculated that with 501 patients, the 
study would have 89% power to detect a 16% 
difference in clinical remission rates, assuming 
rates of 38% and 22% with vedolizumab and 
placebo, respectively.11,16,21-26
R esult s
Patients
A total of 1920 patients were screened (Fig. S1 in 
the Supplementary Appendix), and 1115 were en-
rolled and included in the analyses; 7.6% of them 
did not meet at least one inclusion criterion or 
met at least one exclusion criterion (Table S3 in 
the Supplementary Appendix). In the random-
ized trial of induction therapy involving 368 pa-
tients (cohort 1), the baseline characteristics 
were similar in the placebo and vedolizumab 
groups (Table 1). Approximately 50% of patients 
had previously received TNF antagonist therapy. 
In the randomized trial of maintenance therapy 
involving 461 patients, the baseline characteris-
tics were similar in the placebo and vedolizumab 
groups (Table S4 in the Supplementary Appen-
dix) as well as in patients who entered the main-
Table 1. (Continued.)
Characteristic
Placebo
(N = 148) Vedolizumab
Total
(N = 1115)
Cohort 1
(N = 220)
Cohort 2
(N = 747)
Combined
(N = 967)
Prior TNF antagonist therapy for Crohn’s 
 disease — no./total no. (%)
Receipt of ≥1 TNF antagonist 72/148 (48.6) 111/220 (50.5) 506/747 (67.7) 617/967 (63.8) 689/1115 (61.8)
Failure of TNF antagonist therapy
≥1 TNF antagonist 70/148 (47.3) 105/220 (47.7) 470/747 (62.9) 575/967 (59.5) 645/1115 (57.8)
Inadequate response** 41/70 (58.6) 56/105 (53.3) 223/470 (47.4) 279/575 (48.5) 320/645 (49.6)
Loss of response†† 22/70 (31.4) 40/105 (38.1) 189/470 (40.2) 229/575 (39.8) 251/645 (38.9)
Unacceptable side effects 7/70 (10.0) 9/105 (8.6) 58/470 (12.3) 67/575 (11.7) 74/645 (11.5)
≥2 TNF antagonists 42/148 (28.4) 56/220 (25.5) 300/747 (40.2) 356/967 (36.8) 398/1115 (35.7)
Hemoglobin concentration — g/liter 124.7±18.6 121.6±18.4 125.2±16.8 124.4±17.3 124.4±17.4
White-cell count — ×10 −9/liter 8.8±3.0 9.0±3.3 9.2±3.4 9.2±3.4 9.1±3.4
Prior surgery for Crohn’s disease — no. (%) 54 (36.5) 98 (44.5) 314 (42.0) 412 (42.6) 466 (41.8)
History of fistulizing disease — no. (%) 56 (37.8) 90 (40.9) 264 (35.3) 354 (36.6) 410 (36.8)
Draining fistulae at baseline — no. (%) 23 (15.5) 38 (17.3) 104 (13.9) 142 (14.7) 165 (14.8)
* Plus–minus values are means ±SD. Cohort 1 included patients who were randomly assigned, in a 3:2 ratio, as part of the double-blind trial 
of induction therapy, to receive intravenous vedolizumab, at a dose of 300 mg, or placebo at weeks 0 and 2. Cohort 2 included patients 
who received open-label vedolizumab at a dose of 300 mg at weeks 0 and 2. There were no significant differences (at P<0.05) between the 
placebo group and the vedolizumab group in cohort 1. TNF denotes tumor necrosis factor.
† Race was determined by the investigator.
‡ The Crohn’s Disease Activity Index (CDAI) consists of eight components, each of which is adjusted by a weighting factor. The components 
are subsequently added together to yield a composite score; scores range from 0 to approximately 600, with higher scores indicating more 
severe disease activity.
§ Data on C-reactive protein levels were available for 147 patients in the placebo group, 220 patients in vedolizumab cohort 1, and 747 pa-
tients in vedolizumab cohort 2, for a total of 1114 patients. Among these, 127 patients in the placebo group (86.4%), 183 in vedolizumab 
cohort 1 (83.2%), and 617 in vedolizumab cohort 2 (82.6%) (800 patients [82.7%] in the combined  vedolizumab groups and 917 patients 
[83.2%] in the total population) had elevated C-reactive protein levels (>2.87 mg per liter).
¶ Data on fecal calprotectin concentrations were available for 142 patients in the placebo group, 210 in vedolizumab cohort 1, and 719 in 
 vedolizumab cohort 2.
‖ The glucocorticoids used included prednisone, methylprednisolone, prednisolone, budesonide, hydrocortisone, and triamcinolone. The im-
munosuppressive agents included azathioprine, mercaptopurine, and methotrexate.
** Included in this category were patients who did not have an initial response.
†† Loss of response indicates that the patient had a response initially but subsequently did not have a response.
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tenance trial from cohort 1 (96 patients) and 
those who entered from cohort 2 (365 patients).
End Points in the Trial of Induction Therapy
In an analysis of the two primary end points in 
cohort 1, a total of 32 of the 220 patients who 
received vedolizumab (14.5%) and 10 of the 148 
who received placebo (6.8%) had a clinical re-
mission (P = 0.02) at week 6; 69 (31.4%) and 38 
(25.7%), respectively, had a CDAI-100 response 
(P = 0.23) (Fig. 1A). The efficacy of vedolizumab 
was generally consistent across subgroups (Fig. S2 
in the Supplementary Appendix). Among the 
747 patients in cohort 2, a total of 132 (17.7%) 
had a clinical remission and 257 (34.4%) had a 
CDAI-100 response at week 6.
In cohort 1, the mean changes in C-reactive 
protein levels from baseline to week 6 were similar 
in the vedolizumab and placebo groups (Fig. 1B). 
In a post hoc analysis, the proportion of patients 
who had had C-reactive protein levels above 
2.87 mg per liter at baseline and whose levels 
returned to the normal range (i.e., ≤2.87 mg per 
liter) by week 6 was similar in the two groups 
(Fig. S3 in the Supplementary Appendix).
End Points in the Trial of Maintenance Therapy
At week 52, a total of 60 of the 154 patients 
(39.0%) receiving vedolizumab every 8 weeks 
and 56 of the 154 patients (36.4%) receiving 
vedo liz umab every 4 weeks were in clinical re-
mission, as compared with 33 of the 153 pa-
tients (21.6%) receiving placebo (P< 0.001 and 
P = 0.004 for the comparison of the two vedoliz-
umab groups, respectively, with placebo) (Fig. 2A). 
The efficacy of vedolizumab was generally consis-
tent across subgroups (Fig. S4 in the Supplemen-
tary Appendix).
In an analysis of secondary end points at 
week 52, the proportions of patients who had a 
CDAI-100 response and who had glucocorticoid-
free remission were significantly greater in the 
groups receiving vedolizumab every 8 weeks and 
every 4 weeks than in the placebo group; how-
ever, the proportion of patients with a durable 
clinical remission did not differ significantly 
among the groups (Fig. 2A). Figure 2 shows the 
proportions of patients who met the criteria for 
clinical remission and who had a CDAI-100 re-
sponse; Figure S5 in the Supplementary Appen-
dix shows the mean CDAI scores from week 6 to 
week 52, the mean changes from week 6 in the 
IBDQ score, the mean C-reactive protein levels 
in patients who had had elevated levels at base-
line, and the median change in the glucocorticoid 
dose over time. Information regarding draining 
fistulae is shown in Figure S6 in the Supplemen-
tary Appendix. In a post hoc analysis of data 
from patients who had had elevated C-reactive 
protein levels at week 6, levels returned to the 
normal range (i.e., ≤2.87 mg per liter) by week 52 
in a greater proportion of patients receiving 
 vedolizumab than of patients receiving placebo 
(Fig. S7 in the Supplementary Appendix).
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Figure 1. Primary End Points in the Trial of Induction 
Therapy.
Panel A shows the proportions of patients who were in 
clinical remission and patients who had a CDAI-100 
 response (a decrease of 100 points or more in the 
score on the Crohn’s Disease Activity Index [CDAI], with 
scores ranging from 0 to approximately 600, and with 
higher scores indicating greater disease activity) at 
week 6. Panel B shows the mean C-reactive protein 
(CRP) concentrations at week 0 and week 6. I bars indi-
cate standard errors. For patients with insufficient data 
at the designated analysis time point, the last value was 
carried forward. The P value (two-sided) in Panel B was 
calculated with the use of the Wilcoxon rank-sum test 
for the change from baseline values in CRP concentra-
tions with vedolizumab versus placebo.
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Safety
Nasopharyngitis occurred more frequently, and 
headache and abdominal pain less frequently, 
with vedolizumab than with placebo during the 
trial of maintenance therapy (Table 2, and Table 
S6 in the Supplementary Appendix). The inci-
dences of infections and of serious infections 
were higher with vedolizumab than with placebo 
(Table S6 in the Supplementary Appendix). Dur-
ing the 6-week trial of induction therapy, breast 
cancer developed in one patient who was receiving 
vedolizumab. During the trial of maintenance 
therapy, one case each of latent tuberculosis, 
carcinoid tumor in the appendix, squamous-cell 
carcinoma, and basal-cell skin carcinoma was 
diagnosed in the vedolizumab groups; a border-
line ovarian tumor developed in one patient in 
the placebo group. The incidence of any serious 
adverse event was higher among patients who re-
ceived vedolizumab than among those who re-
ceived placebo (24.4% vs. 15.3%).
Five deaths occurred during the study period 
(see the Supplementary Appendix), four among 
patients receiving vedolizumab (one death each 
from Crohn’s disease with sepsis, intentional 
overdose of prescription medication, myocardi-
tis, and septic shock) and one in the placebo 
group (from bronchopneumonia). The sepsis 
and septic-shock events (both culture-negative) 
involved, respectively, a patient with extensive 
preexisting pulmonary emboli and a thrombus 
in the inferior vena cava and a patient with 
medically managed pneumoperitoneum after 
colonoscopy. Myocarditis and intravenous injec-
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Figure 2. End Points in the Trial of Maintenance 
 Therapy.
Panel A shows the proportions of patients, among those 
who had had clinical remission at week 6, who were still 
in clinical remission at week 52, who had a CDAI-100 
response at week 52, and who had glucocorticoid-free 
remission (i.e., clinical remission without glucocorti-
coid therapy) at week 52 (with data for this end point 
available for 82 patients receiving placebo, 82 patients 
receiving  vedolizumab every 8 weeks, and 80 patients 
receiving vedolizumab every 4 weeks), as well as the 
proportion of patients who had a durable clinical remis-
sion (defined as a clinical remission at ≥80% of study 
visits,  including the final visit) at week 52. Panel B shows 
the proportions of patients who were in clinical remis-
sion from week 6 to week 52, and Panel C, the propor-
tions of patients who had a CDAI-100 response from 
week 6 to week 52.
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tion of drugs intended for oral use were diag-
nosed at autopsy in a patient who had a history 
of endocarditis and deep-vein thrombosis.
Patients were actively monitored for PML (see 
the Supplementary Appendix); no cases were iden-
tified. Clinically important infusion reactions were 
infrequent; only one patient discontinued the study 
treatment because of a serious infusion reaction. 
No cases of anaphylaxis were reported.
Pharmacokinetics and Immunogenicity
The mean (±SD) trough vedolizumab concentra-
tion in the 827 patients with pharmacokinetic 
data that could be evaluated was 26.8±17.5 μg 
per milliliter at week 6. At steady state, the mean 
vedolizumab concentrations were 13.0±9.1 μg 
per milliliter in the group receiving vedolizumab 
every 8 weeks (72 patients with data that could 
be evaluated) and 34.8±22.6 μg per milliliter in 
the group receiving vedolizumab every 4 weeks 
(247 patients with data that could be evaluated). 
Correlations between drug level and response in 
the trials of induction and maintenance therapy 
are shown in Figures S8 and S9, respectively, in 
the Supplementary Appendix. Both doses were as-
sociated with target saturation that exceeded 95% 
in more than 95% of the study population. Among 
814 ved olizumab-treated patients with samples 
that could be evaluated for antibodies against ve-
dolizumab, 33 patients (4.1%) had at least one 
sample with positive test results and 3 (0.4%) had 
two or more consecutive samples with positive 
results. Concomitant immunosuppressive therapy 
was associated with decreased immunogenicity 
(data not shown).
Discussion
Among patients with moderately to severely active 
Crohn’s disease in whom conventional therapy 
failed, patients treated with vedolizumab induc-
tion therapy were more likely than those receiving 
placebo to have a remission at week 6; however, 
they were not more likely to have a CDAI-100 
 response. In an analysis of patients who had 
a response to induction therapy with vedoliz-
umab, the rates of clinical remission, CDAI-100 
response, and glucocorticoid-free remission at 
week 52 were higher among patients receiving 
vedo lizumab every 8 weeks or every 4 weeks than 
among patients who were switched to placebo.
Many patients with moderately to severely ac-
tive Crohn’s disease do not have a response to 
currently available treatments or have an initial 
response that is not sustained.23,26-28 The effi-
cacy of a second TNF antagonist in patients who 
Table 2. Adverse Events Affecting at Least 5% of Patients Who Received 
Vedolizumab.*
Event
Placebo 
(N = 301)
Vedolizumab 
(N = 814)
no. (%)
Adverse event
Crohn’s disease exacerbation 65 (21.6) 164 (20.1)
Arthralgia 40 (13.3) 110 (13.5)
Pyrexia 40 (13.3) 103 (12.7)
Nasopharyngitis 24 (8.0) 100 (12.3)
Headache 47 (15.6) 97 (11.9)
Nausea 30 (10.0) 90 (11.1)
Abdominal pain 39 (13.0) 79 (9.7)
Upper respiratory tract infection 17 (5.6) 54 (6.6)
Fatigue 14 (4.7) 53 (6.5)
Vomiting 23 (7.6) 49 (6.0)
Back pain 12 (4.0) 38 (4.7)
Any serious adverse event 46 (15.3) 199 (24.4)
Any serious infection† 9 (3.0) 45 (5.5)
Any cancer‡ 1 (0.3) 4 (0.5)
* The analysis of adverse events was performed on data from the safety popula-
tion, which included all patients who received at least one dose of the study 
drug. For this analysis, the vedolizumab group includes patients who received 
maintenance therapy with vedolizumab (i.e., those who had had a response to 
vedolizumab induction therapy and were randomly assigned to receive vedo-
lizumab every 8 weeks or  every 4 weeks as maintenance therapy plus those 
who did not have a response to vedolizumab induction therapy and continued 
to receive vedolizumab every 4 weeks during the maintenance trial); the place-
bo group includes patients who did not receive maintenance therapy with ve-
dolizumab (i.e., those who were randomly assigned to placebo during the in-
duction trial plus those who had had a response to vedolizumab induction 
therapy and were randomly assigned to placebo for the maintenance trial). 
See Tables S5 and S6 in the Supplementary Appendix for a further breakdown 
of individual treatment groups. Adverse events were classified according to the 
System Organ Class categorization and preferred terms in the Medical Dictionary 
for Regulatory Activities (MedDRA), version 15. Patients with more than one 
event in a category were counted only once if the start and stop dates of the 
multiple events overlapped or if the start and stop dates were the same; if the 
start and stop dates of the multiple events did not overlap, they were counted 
as separate events.
† A serious infection was defined as a serious adverse event of infection accord-
ing to the classification for adverse event  reporting in MedDRA.
‡ The cancer in the placebo group was a borderline ovarian carcinoma, which is 
defined as a subset of epithelial ovarian tumors that are considered to be of 
low malignant potential. The cancers in the vedolizumab group included one 
case each of basal-cell skin carcinoma, breast cancer, carcinoid tumor in the 
appendix, and squamous-cell carcinoma of the skin.
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no longer have a response to a first TNF antago-
nist is lower than the efficacy of the first TNF 
antagonist in patients who have never received 
TNF-antagonist therapy.24 Although natalizumab 
is efficacious in Crohn’s disease, it is used in-
frequently10-12 because of the risk of PML.13 
Thus, novel treatment strategies are needed.16-18 
Selective blockade of α4β7-expressing, gut-homing 
lymphocytes with vedolizumab represents one 
potential approach.16-18
The modest effect of vedolizumab on the 
induction of clinical remission and its non-
significant effect on the CDAI-100 response at 
week 6 require consideration. Whether these 
effects are attributable primarily to modest ef-
ficacy or to potential confounders is unknown. 
One possible confounder is the severity of dis-
ease in the study population, which may have 
precluded a robust inductive effect. Patients 
had a mean baseline CDAI score of 324 points, 
a median C-reactive protein concentration of 
11.5 mg per liter, and a median fecal calprotec-
tin value of 686 μg per gram; 37% had a his-
tory of fistulizing disease, and 42% had under-
gone at least one previous surgery for Crohn’s 
disease. Approximately 50% of patients had had 
treatment failure (which was defined in the 
protocol as a lack of initial response, loss of 
response, or unacceptable side effects) with one 
or more TNF antagonists; half of these patients 
did not have an initial response.  Approximately 
30% of patients had had treatment failure with 
two or more TNF antagonists. A population 
with such refractory disease has not been evalu-
ated in previous trials of TNF antagonists. 
However, a recent clinical trial of ustekinumab 
in a similar population also showed a modest 
induction effect with respect to the CDAI-100 
response at week 6 but did not show a signifi-
cant effect on remission rates.29 Protracted 
medical management with multiple medica-
tions, including TNF antagonists, may contrib-
ute to the refractoriness of the disease. Alterna-
tively, pharmacologic inhibition of lymphocyte 
migration to the gut may require more time for 
full induction efficacy than that required with 
TNF blockade. In addition, anti-integrin thera-
py could be relatively slower acting in Crohn’s 
disease, given the transmural nature of the dis-
ease, with the predominant benefit seen during 
the maintenance phase (Fig. 2, and Fig. S5 in 
the Supplementary Appendix). Previous studies 
of natalizumab showed modest induction bene-
fits, rising response and remission rates over the 
course of 12 weeks, and robust maintenance ef-
fects, suggesting that vedoliz umab may have 
similar kinetic characteristics.10-12 Differences 
between the vedolizumab and placebo groups 
during the trial of maintenance therapy were not 
apparent until week 28 or later (Fig. 2B and 2C), 
possibly owing to the time required for vedoliz-
umab clearance after two induction doses.
During the maintenance phase, serious infec-
tions occurred in 5.5% of the patients receiving 
vedolizumab, as compared with 3.0% of the pa-
tients receiving placebo. PML developed in none 
of the 1115 patients who entered this study — a 
finding consistent with that in a parallel study 
of patients with ulcerative colitis, which appears 
elsewhere in this issue of the Journal.30 This trial 
did not have a long enough duration or a large 
enough sample to exclude the possibility of an 
association of vedolizumab with the risk of PML; 
longer-term observational data are needed.
Among approximately 3000 patients exposed 
to vedolizumab for a median of 18.8 months 
(mean, 20.9 months; range, 4 to 67), no cases of 
PML were reported as of February 2013 (unpub-
lished data from Millennium clinical trials). Ap-
proximately 80% of patients had received immu-
nosuppressive agents previously, and 900 patients 
(approximately 30%) had more than 24 months 
of vedolizumab exposure. Owing to the lack of 
a commercially available validated assay, JC virus 
antibody status was not assessed. However, sero-
positivity rates of at least 50% have been reported 
in similar populations with Crohn’s disease.31-38 
In patients with multiple sclerosis receiving na-
talizumab therapy, the overall incidence of PML 
is more than 1 case in 500 patients (2.0 per 1000; 
range, approximately 1 in 3000 [0.3 per 1000] with 
≤24 months of exposure and no prior immuno-
suppressive therapy to approximately 1 in 150 
[6.7 per 1000] with >24 months of exposure and 
prior immunosuppressive therapy).13
The rate of 5 deaths per 1115 patients ob-
served in this study (see the Supplementary Ap-
pendix) is similar to crude rates of death associ-
ated with other biologic medications.11,23,25-27 
Cancer was reported in 4 patients treated with 
vedolizumab (two solid tumors and two non-
melanoma skin cancers). Long-term epidemio-
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logic studies are needed to fully characterize the 
safety of vedolizumab.
This study leaves some questions unanswered, 
including which specific patients with Crohn’s 
disease may derive the most benefit from vedoliz-
umab. In addition, the study design did not allow 
for adequate assessment of potential synergistic 
effects of combining vedolizumab with immuno-
suppressive agents.
In conclusion, patients with moderately to 
severely active Crohn’s disease who were treated 
with vedolizumab, as compared with those re-
ceiving placebo, were more likely to have a clini-
cal remission at week 6 but were not more likely 
to have a CDAI-100 response. Among patients 
who had a response to vedolizumab at week 6, 
the rates of clinical remission at week 52 were 
significantly higher among patients receiving ve-
dolizumab every 8 weeks or every 4 weeks than 
among those receiving placebo.
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